Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...

The artificial intelligence community is raving over a new reasoning model that has surprised even Silicon Valley.

In this video, Xiuning Le, MD, PhD, discusses the state of the pipeline for developing EGFR-mutated lung cancer treatments.

This differentiated safety profile sets OQY-3258 apart from other TROP2 ADCs. “The compelling clinical activity demonstrated in our Phase 1a/1b trial highlights the potential of OQY-3258 to ...

On January 27, the company announced improvements to its RADR® AI platform aimed at accelerating and optimizing the development of antibody-drug conjugates (ADCs). ADC is a process of creating ...

Tubulis continues expansion of its clinical pipeline with a second ADC drug candidate entering the clinic TUB-030 is a next-generation ADC targeting 5T4 with an exatecan payload, developed ...

Genmab A/S (NASDAQ:GMAB), a Danish biotechnology company specializing in antibody therapeutics for cancer treatment, finds itself at a crucial juncture. With a strong portfolio of approved medicines ...